In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? (Q38984450)

8 September 2017

title

In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? (English)

1 reference

8 September 2017

1 reference

hepatocellular carcinoma

1 reference

11

Guido Gerken

1 reference

8 September 2017

10

Andreas Bockisch

1 reference

8 September 2017

Amr El Fouly

1

1 reference

8 September 2017

Judith Ertle

2

1 reference

8 September 2017

Ahmed El Dorry

3

1 reference

8 September 2017

Mohamed K Shaker

4

1 reference

8 September 2017

Alexander Dechêne

5

1 reference

8 September 2017

Heba Abdella

6

1 reference

8 September 2017

Stefan Mueller

7

1 reference

8 September 2017

Eman Barakat

8

1 reference

8 September 2017

Thomas Lauenstein

9

1 reference

8 September 2017

Joerg F Schlaak

12

1 reference

8 September 2017

publication date

2 August 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

35

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

627-635

1 reference

Epidemiology of hepatocellular carcinoma in Hispanics in the United States

8 September 2017

cites work

1 reference

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

Prospective validation of the Barcelona Clinic Liver Cancer staging system

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival

21 January 2018

1 reference

Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation

21 January 2018

1 reference

A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation

21 January 2018

1 reference

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

21 January 2018

1 reference

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

21 January 2018

1 reference

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.

21 January 2018

1 reference

SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer

21 January 2018

1 reference

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients

21 January 2018

1 reference

Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer

21 January 2018

1 reference

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

21 January 2018

1 reference

Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization

21 January 2018

1 reference

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

21 January 2018

1 reference

Is radioembolization ready for the barcelona clinic liver cancer staging system?

21 January 2018

1 reference

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors

21 January 2018

1 reference

Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12637

1 reference

8 September 2017

1 reference